A

Alberta Health Services | Alberta Children's Hospital, Department of Neurosciences

Research site

(Unclaimed)

Location

28 Oki Drive North East, Calgary, Alberta, Canada

Site insights

Top conditions

Top treatments

Macitentan

Dexamethasone

Lebrikizumab

TAK-659

CyBorD

Acetylsalicyclic acid

S42909

Oseltamivir

Tadalafil

MHAA4549A

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 19 total trials

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared...

Active, not recruiting

Amyloidosis

Drug: Daratumumab

Drug: Cyclophosphamide

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (A DUE)

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of...

Active, not recruiting

Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Drug: Placebo tadalafil

Drug: Macitentan 10 mg